Michael Lauseker

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 417 citations

Life Sciences, Molecular Biology, Oncology +16

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

Rüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz et al. · Journal of Clinical Oncology · 2011 · 323 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +12

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

Rüdiger Hehlmann, Martin C. Müller, Michael Lauseker et al. · Journal of Clinical Oncology · 2013 · 299 citations · Full text

Medicine, Hematology, Pharmacology +13

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Alice Fabarius, Armin Leitner, Andreas Hochhaus et al. · Blood · 2011 · 290 citations

Life Sciences, Genetics, Hematology +16